Seres Therapeutics, Inc. (MCRB) — 10-Q Filings

10-Q Filings (6)

• Seres Therapeutics Swings to Profit on VOWST Sale, Cash Up — Nov 5, 2025 Risk: high
  Seres Therapeutics, Inc. (MCRB) reported a net income from continuing operations of $21.03 million for the nine months ended September 30, 2025, a significant i
• Seres Therapeutics Q2 Loss Widens to $60.5M Amid Strategic Pivot — Aug 6, 2025 Risk: high
  Seres Therapeutics, Inc. (MCRB) reported a net loss of $60.5 million for the second quarter of 2025, a significant increase from the $45.2 million net loss in t
• Seres Therapeutics Files Q1 2025 10-Q — May 7, 2025 Risk: medium
  Seres Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and business operations. Key event
• Seres Therapeutics Files Q3 2024 10-Q — Nov 13, 2024 Risk: medium
  Seres Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the nine months end
• Seres Therapeutics Q2 2024 Update: R&D Expenses and Nestle Deal — Aug 13, 2024 Risk: medium
  Seres Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses for the first six months of
• Seres Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk: medium
  Seres Therapeutics, Inc. (MCRB) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Seres Therapeutics, Inc. filed a 10-Q report on May 8, 2024, for th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX